As we’ve stated over the past several weeks, AdverseEvents is not a fan of drug manufacturer and payer exclusivity deals. We believe strongly that they are not in the best interest of drug safety and set a dangerous precedent.
The veracity of our beliefs was demonstrated by the results revealed from the comparative safety research we conducted on Abbvie’s Viekira Pak and Gilead’s Harvoni / Sovaldi. Viekira Pak’s inferior safety profile confirmed that Express Scripts made the wrong decision to exclusively place it on its’ National Preferred Formulary.
Related Read: Did Express Scripts Choose the Right Hepatitis C Drug?
Since our initial comments on Express Scripts’ and CVS’ respective deals, most of the other big name payers have made similar arrangements. Here’s the breakdown of who is covering what (publically) as of January 27, 2015:
|Gilead’s Harvoni / Solvadi||Abbvie’s Viekira Pak||Both Drugs|
|CVS Healthcare||Express Scripts||Prime Therapeutics|
If we take Prime out of the mix, that is 6-1 in favor of Harvoni/Sovaldi.
I guess we aren’t the only ones that think Express Scripts made the wrong decision. Public drug safety and long term cost savings, should always win out over short-term profits.
You can see our head-to-head comparison of the safety profiles of Harvoni, Sovaldi and Viekiera Pak drugs here.
Executive Vice President